Neurotech International Ltd
Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company.
The business
Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company focuses predominately on pediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomized, double-blind, placebo-controlled clinical trial in autism spectrum disorder (ASD). In addition, it has completed and reported significant and clinically meaningful Phase I/II trials in ASD and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved. The Company’s subsidiaries include AAT Research Ltd and AAT Medical Ltd.
Small Caps Research
No research on Neurotech International Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise NTI based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Neurotech International Granted FDA Clearance for US Paediatric Study of NTI164
Neurotech's NTI164 gets FDA IND clearance for US trial; kicks off PopPK study, paving global regulatory path ahead of potential autism therapy approvals.
Neurotech International Secures HREC Approval for Pivotal Phase 3 ASD Study of NTI164
Neurotech International wins HREC approval to launch pivotal Phase 3 ASD trial for NTI164, opening path to TGA/FDA submissions and regulatory milestones.
Neurotech International admits final patient for NTI164 Phase II/III trial to treat autism
Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has confirmed that the last patient in a Phase II/III NTIASD2 clinical trial for children with autism spectrum disorder (ASD) has completed their final visit. The child was the 54th patient to take part in the trial, which recruited individuals between the ages of 8 and 17 […]
Australian biotech sector tipped for strong growth
Recent studies have highlighted the significant potential the Australian biotech industry has ahead of it. International research firm KPMG recently forecast Australia could generate over $15 billion in exports to the United States and create 34,000 high-skilled jobs by accelerating US-Australia biotechnology collaboration. Australia’s $1.2b biotech industry currently ranks fifth in the world in terms […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.